中文版 | English
Title

Malignant mediastinal mesothelioma treated with anlotinib: a case report and review of the literature

Author
Corresponding AuthorCao, Hua; Xu, Ruilian
Publication Years
2023-05-16
DOI
Source Title
ISSN
2234-943X
Volume13
Abstract
Malignant mesothelioma that originates from mediastinal (MMM) is a rare form of malignant pleural mesothelioma (MPM). The prognosis of advanced stage MPM was poor, and the traditional treatment was chemotherapy. Here, we present a patient with MMM that was treated with anlotinib, a multitargeted tyrosine kinase inhibitor (TKI) who had a 24-month progression-free survival (PFS). Further review of the literature showed that, despite some explorations of applying small-molecule multitargeted TKIs in the treatment of MPM, until today, no large series had a positive result. Anlotinib had been approved by the China Food and Drug Administration on treating non-small cell lung cancer, soft tissue sarcoma, renal cell carcinoma, and medullary thyroid cancer. We assumed that the ability of anlotinib to target more tyrosine kinase receptors than most of other TKIs could contribute to the long duration of PFS in this case, but further study is needed to further validate the efficacy of anlotinib in treatment of MPM.
Keywords
URL[Source Record]
Indexed By
Language
English
SUSTech Authorship
First ; Corresponding
WOS Research Area
Oncology
WOS Subject
Oncology
WOS Accession No
WOS:000998595100001
Publisher
Data Source
Web of Science
Citation statistics
Document TypeJournal Article
Identifierhttp://kc.sustech.edu.cn/handle/2SGJ60CL/583106
DepartmentShenzhen People's Hospital
Affiliation
1.Southern Univ Sci & Technol, Affiliated Hosp 1, Shenzhen Peoples Hosp, Jinan Univ,Southern Univ Sci & Technol,Dept Oncol,, Shenzhen, Peoples R China
2.Southern Univ Sci & Technol, Affiliated Hosp 1, Shenzhen Peoples Hosp, Jinan Univ,Dept Spine Surg,Clin Med Coll 2, Shenzhen, Peoples R China
First Author AffilicationShenzhen People's Hospital
Corresponding Author AffilicationShenzhen People's Hospital
First Author's First AffilicationShenzhen People's Hospital
Recommended Citation
GB/T 7714
Zhang, Yishi,He, Wan,Zhan, Ke,et al. Malignant mediastinal mesothelioma treated with anlotinib: a case report and review of the literature[J]. FRONTIERS IN ONCOLOGY,2023,13.
APA
Zhang, Yishi,He, Wan,Zhan, Ke,Zhang, Luobin,Cao, Hua,&Xu, Ruilian.(2023).Malignant mediastinal mesothelioma treated with anlotinib: a case report and review of the literature.FRONTIERS IN ONCOLOGY,13.
MLA
Zhang, Yishi,et al."Malignant mediastinal mesothelioma treated with anlotinib: a case report and review of the literature".FRONTIERS IN ONCOLOGY 13(2023).
Files in This Item:
There are no files associated with this item.
Related Services
Fulltext link
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Export to Excel
Export to Csv
Altmetrics Score
Google Scholar
Similar articles in Google Scholar
[Zhang, Yishi]'s Articles
[He, Wan]'s Articles
[Zhan, Ke]'s Articles
Baidu Scholar
Similar articles in Baidu Scholar
[Zhang, Yishi]'s Articles
[He, Wan]'s Articles
[Zhan, Ke]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Zhang, Yishi]'s Articles
[He, Wan]'s Articles
[Zhan, Ke]'s Articles
Terms of Use
No data!
Social Bookmark/Share
No comment.

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.